Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality in the United States. Recent evidence suggests women, in comparison to men, experience greater CVD related mortality, may have inferior responses to treatment, and are at greater risk of adverse drug events. However, from drug development to safety, tolerability and efficacy testing, insufficient attention has been given to sex differences in patient responses to pharmacologic agents. Moreover, randomized controlled trials, even large multicenter studies, are generally underpowered to detect heterogeneity in efficacy or safety, including any existing sex differences. Our preliminary results further suggest that standard analytic approaches for assessing sex differences in non-experimental research may lead to estimated sex-specific treatment effects that are biased. Therefore, our overall objectives are to develop, test, implement, and disseminate reliable and innovative methods for evaluating sex differences in the comparative effectiveness and safety of CVD pharmacotherapy.
Our specific aims are to: 1) identify conditions under which common analytic methods are likely to produce biased estimates of treatment effects in men and/or women;2) develop innovative alternative analytic methods that validly and reliably evaluate sex differences;3) test the performance of these innovative methods and the standard analytic approaches in a large scale Monte Carlo simulation study; and 4) apply and validate methods for quantifying sex differences in the safety and effectiveness of pharmacotherapy. We will use national administrative claims data supplemented by survey and laboratory data enabling us to deliver timely answers to these urgent clinical questions with immediate implications for clinical practice. Moreover, the innovative and novel analytic methods we will develop and implement in this proposal will be applicable broadly to the study of other important patient subgroups (such as those defined by race, ethnicity and age), and will be equally relevant across the full spectrum of health conditions and their clinical management.
The findings will impact health and health care by informing risks, benefits, and sex differences in the effects of lipid lowering drugs - currently used by nearly 20 million Americans. By using national administrative claims databases supplemented by rich laboratory and survey data, we leverage our existing resources and deliver timely answers to urgent clinical questions with immediate implications at the bedside. The innovative methods we will develop have application to other subgroups (e.g., minorities, children), and will be equally relevant across the spectrum of clinical concerns from infectious agents to medical devices. In the emerging era of personalized medicine, it is essential that our analytic methods are honed and chosen carefully for the important challenges that face researchers and the stakeholders who rely on their findings.
|Htoo, Phyo T; Buse, John B; Gokhale, Mugdha et al. (2016) Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors. Eur J Clin Pharmacol 72:1013-23|
|Kinlaw, Alan C; Jonsson Funk, Michele; Steiner, Michael J et al. (2016) Trends in Pharmacotherapy for Bladder Dysfunction Among Children in the United States, 2000 to 2013. Clin Pediatr (Phila) :|
|JirÃ³n, Marcela; Pate, Virginia; Hanson, Laura C et al. (2016) Trends in Prevalence and Determinants of Potentially Inappropriate Prescribing in the United States: 2007 to 2012. J Am Geriatr Soc 64:788-97|
|Young, Jessica C; StÃ¼rmer, Til; Lund, Jennifer L et al. (2016) Predictors of prevalent statin use among older adults identified as statin initiators based on Medicare claims data. Pharmacoepidemiol Drug Saf 25:836-43|
|Wyss, Richard; Ellis, Alan R; Brookhart, M Alan et al. (2015) Matching on the disease risk score in comparative effectiveness research of new treatments. Pharmacoepidemiol Drug Saf 24:951-61|
|Conover, Mitchell M; Howell, Jennifer O; Wu, Jennifer M et al. (2015) Incidence of opioid-managed pelvic pain after hysteroscopic sterilization versus laparoscopic sterilization, US 2005-2012. Pharmacoepidemiol Drug Saf 24:875-84|
|Funk, Michele Jonsson; Landi, Suzanne N (2014) Misclassification in administrative claims data: quantifying the impact on treatment effect estimates. Curr Epidemiol Rep 1:175-185|